OWKIN demonstrated that FGFR3 status determines eligibility for erdafitinib, with the model predicting FGFR3 mutation status in bladder cancer.
Public source
Publisher name
Public post
📄 HistoPLUS is now peer-reviewed and published open access in the Journal of Pathology Informatics. When we released the preprint last August, HistoPLUS was a cell dete…
Company
OWKIN
From token to patient impact
- Industry
- Technology, Information and Internet
- Location
- New York, US
- Company size
- 201–500 employees
About OWKIN
Owkin is the vertical patient-driven layer that turns model companies frontier intelligence into expert- and experimentally validated biomedical outcomes, creating a new biology step to AGI.
See moreLatest activity
Latest activity from OWKIN
16 signals
Products & Services
OWKIN announced the launch of Initiative W, an independent, science-led effort focused on the safe development of AI at the intersection of biology and healthcare.
Presence & Recognition
OWKIN is heading to BioTechX Europe 2026 in Basel from October 6 to 8.
People
OWKIN hired Bryan Ly as a Research Intern to work within the Drug Discovery team on generative approaches, particularly flow matching models.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
SOPHiA GENETICS
SOPHiA GENETICS published real-world evidence showing nearly 4,800 patients across Spain accessing HRD testing without sending samples to a single lab.
Research & Knowledge
Cure51
Cure51 published a Rosalind Study combining multiple layers of patient data, including genomics, transcriptomics, pathology, clinical history, and multi-omics insights, to integrate complex datasets and identify patterns for AI-driven treatment prediction.
Research & Knowledge
Pierre Fabre Oncology
Pierre Fabre Oncology conducted a project with Laboratoires Pierre Fabre and Filière Intelligence Artificielle & Cancers in NSCLC to describe the molecular testing pathway and identify factors impacting therapeutic decisions.
Research & Knowledge
iOMEDICO
iOMEDICO published the final results of the REALTRK registry on rare NTRK fusion-positive cancers in JCO Precision Oncology, including 47 adults with advanced solid tumors and 26 patients who received TRK inhibitor therapy.
Research & Knowledge
Pharmatica